Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Clinical trial NCT01773785 · TERMINATED
Trial details
- NCT number
- NCT01773785
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-04-01
- Primary completion
- 2015-09-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.